


DISCOVER VAZALORE®—THE FIRST AND ONLY LIQUID-FILLED ASPIRIN CAPSULES™



The information contained in this document is intended for healthcare professionals only.

VAZALORE's unique delivery system is intended to predictably release aspirin in the duodenum and decrease exposure to the stomach, which is the most susceptible part of the GI tract to NSAID-induced local gastric injury.


VAZALORE is specially designed to help protect the stomach

Preassociating the aspirin in VAZALORE to our pharmaceutical lipid limits the aspirin from interacting with similar naturally occurring phospholipids in the stomach lining, helping to prevent local gastric injury.




LIMITS DIRECT CONTACT

VAZALORE's complex remains stable in the low pH of the stomach, limiting direct contact between aspirin and the gastric mucosa



TARGETED DELIVERY

Once the complex arrives in the duodenum, it dissociates in the higher-pH environment and aspirin is free to be absorbed



FAST, PREDICTABLE ABSORPTION

This drug delivery system is intended to predictably release aspirin in the duodenum to optimize absorption



REASSEMBLES DURING REFLUX

Even if reflux occurs and aspirin and lipidic excipients return to the stomach, they reassemble into the complex, limiting direct stomach contact

VAZALORE is available in 81 mg and 325 mg doses



for secondary prevention of vascular events



for secondary prevention of vascular events; pain reliever; fever reducer

HEART PROTECTION WITH THEIR STOMACH IN MIND™



The information contained in this document is intended for healthcare professionals only.

With VAZALORE, your patients will receive the benefits of the first major innovation in aspirin therapy in over 50 years.

This innovative, FDA-approved liquid-filled aspirin capsule offers:



Bioequivalence to immediate release aspirin with fast predictable antiplatelet activity¹



A unique, lipid-based delivery system designed to **help protect the stomach**



Targeted release in the duodenum to optimize absorption

VAZALORE 325 mg has rigorous clinical studies^{2,3}

See **325 mg Clinical Data sheet** on VazaloreHCP.com or scan the QR code below.



**RECOMMEND THE FIRST AND ONLY
LIQUID-FILLED ASPIRIN CAPSULES™**

References: **1.** Angiolillo DJ et al. Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid-aspirin complex: results of a randomized, crossover, bioequivalence study. *J Thromb Thrombolysis*. 2019;48(4):554-562. **2.** Bhatt DL et al. Enteric coating and aspirin nonresponsiveness in patients with type 2 diabetes mellitus. *J Am Coll Cardiol*. 2017;69(6):603-612. **3.** Cryer B et al. Low-dose aspirin-induced ulceration is attenuated by aspirin-phosphatidylcholine: a randomized clinical trial. *Am J Gastroenterol*. 2011;106(2):272-277.

**To learn more about
how VAZALORE can
help your patients,
visit VazaloreHCP.com**

